MK-0429   Click here for help

GtoPdb Ligand ID: 9689

Synonyms: compound 6 [PMID:14561098] [1] | MK-429 | MK0429
Compound class: Synthetic organic
Comment: MK-0429 is an orally active, non-peptide inhibitor/antagonist of αv integrins [1-2,4]. It was initially identified as a clinical lead with potential utility for the prevention and treatment of osteoporosis [1], but has since shown activity in other biological settings. MK-0429 binds to the αv's Arg-Gly-Asp (RGD)-motif binding domain (the RGD-motif is a conserved sequence in proteins that bind to αv integrins), thereby preventing interaction with RGD-containing binding partners such as osteopontin, bone sialoprotein, vitronectin, and fibrinogen.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 107.89
Molecular weight 439.22
XLogP 1.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cn1)C(N1CCN(C1=O)CCCc1ccc2c(n1)NCCC2)CC(=O)O
Isomeric SMILES COc1ccc(cn1)[C@@H](N1CCN(C1=O)CCCc1ccc2c(n1)NCCC2)CC(=O)O
InChI InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1
InChI Key HGFOOLONGOBCMP-IBGZPJMESA-N
Bioactivity Comments
MK-0429 has shown efficacy in reducing melanoma metastasis in vivo [2], and effects a significant reduction in proteinuria, kidney fibrosis, and collagen accumulation in a rat model of diabetic nephropathy [4]
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin, alpha V subunit Hs Antagonist Antagonist 7.1 pIC50 - 1
pIC50 7.1 (IC50 8x10-8 M) [1]
Description: Binding to the αvβ3 integrin using a scintillation-proximity assay (SPAV3).